4-(4-氰基苯氧基)哌啶-1-羧酸叔丁酯 | 333954-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-氰基苯氧基)哌啶-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate
• CAS: 333954-86-2
• 化学式: C₁₇H₂₂N₂O₃
• mdl: MFCD14155813
• 分子量: 302.373
• InChiKey: ODHVBWQNZTWKCV-UHFFFAOYSA-N

物化性质

• 沸点：
  443.9±35.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.529
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(1-BOC-Piperidin-4-yloxy)benzonitrile
Synonyms: t-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(1-BOC-Piperidin-4-yloxy)benzonitrile
CAS number: 333954-86-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H22N2O3
Molecular weight: 302.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氰基苯氧基)哌啶-1-羧酸叔丁酯 在 盐酸 作用下， 以71 %的产率得到4-(哌啶-4-氧基)-苯甲腈盐酸盐
  参考文献：
  名称：

  ISOQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, COMPRISING SAME AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1)-ASSOCIATED DISEASE

  摘要：

  本发明涉及异喹啉酮衍生物、其制备方法以及用于预防或治疗与聚(ADP-核糖)聚合酶-1(PARP-1)有关的疾病的药物组合物，其中该异喹啉酮衍生物在纳摩尔单位浓度下表现出优异的PARP-1抑制作用，并在眼科疾病或障碍，特别是视网膜疾病方面表现出优异的细胞保护作用（凋亡抑制作用），因此可以有效地用作预防或治疗PARP-1相关疾病（例如眼科疾病或障碍）的药物组合物的活性成分。

  公开号：

  EP4053106A1
• 作为产物：
  描述：

  对氟苯腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以91%的产率得到4-(4-氰基苯氧基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  WO2007/106705

  摘要：

  公开号：

文献信息

• 4-Phenoxypiperidines:  Potent, Conformationally Restricted, Non-Imidazole Histamine H₃ Antagonists
  作者：Curt A. Dvorak、Richard Apodaca、Ann J. Barbier、Craig W. Berridge、Sandy J. Wilson、Jamin D. Boggs、Wei Xiao、Timothy W. Lovenberg、Nicholas I. Carruthers

  DOI：10.1021/jm049212n

  日期：2005.3.1

  activity was determined at the recombinant human H(3) receptor and several members of these new series were found to be potent H(3) antagonists. The present compounds contain a 4-phenoxypiperidine core, which behaves as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole histamine H(3) ligands. One selected member of the new series

  制备了两个新的4-（1-烷基-哌啶-4-基氧基）-苄腈和4-（1-异丙基-哌啶-4-基氧基）-苄胺。在重组人H（3）受体确定了体外活性，并发现这些新系列的几个成员是有效的H（3）拮抗剂。本发明化合物包含4-苯氧基哌啶核心，其表现为许多先前描述的非咪唑组胺H（3）配体共有的3-氨基-1-丙醇部分的构象受限形式。发现该新系列的一个选定成员4- [4-（1-异丙基-哌啶丁-4-基氧基）-苄基]-吗啉（13g）是一种有效的，高度选择性的H（3）受体拮抗剂低至1 mg / kg sc的大鼠脑电图觉醒模型的体内功效。
• [EN] MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS<br/>[FR] MULTIPLES A(NTA)GONISTES DE D2/ANTAGONISTES DE H3 POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU SNC
  申请人：AAPA B V

  公开号：WO2015069110A1

  公开（公告）日：2015-05-14

  The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

  本发明涉及按照式（III）的化合物；以及其药学上可接受的盐、水合物和溶剂合物。这些化合物具有D2受体拮抗/(部分)激动剂效应和H3拮抗效应，以及其药物组合物，以及将其用于预防或治疗中枢神经系统疾病的方法。
• 端锚聚合酶抑制剂
  申请人：北京四环制药有限公司

  公开号：CN107226807B

  公开（公告）日：2021-01-01

  本发明属于医药技术领域，具体涉及通式(Ⅰ)所示的端锚聚合酶抑制剂、其药学上可接受的盐、酯、溶剂化物或其立体异构体，其中R1、R2、R3、m、n、Z、L、Q、A、X1、X2和Y如说明书中所定义。本发明还涉及这些化合物的制备方法，含有这些化合物的药物制剂和药物组合物，以及该化合物、其药学上可接受的盐、酯、溶剂化物或其立体异构体在制备治疗和/或预防由端锚聚合酶介导的癌症及相关疾病的药物中的应用。
• [EN] BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES<br/>[FR] COMPOSES BENZAMIDE BICYCLIQUES TENANT LIEU DE LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE, UTILES DANS LE TRAITEMENT DES MALADIES NEUROLOGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004037788A1

  公开（公告）日：2004-05-06

  The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型双环苯甲酰胺衍生物，其制备方法，含有它们的组合物以及它们在治疗神经系统和精神疾病中的应用。
• [EN] NOVEL OXADIAZOLES<br/>[FR] NOUVEAUX OXADIAZOLES
  申请人：PI INDUSTRIES LTD

  公开号：WO2020070610A1

  公开（公告）日：2020-04-09

  The present invention relates to novel compound of Formula I, wherein, R1, A1, A2, A3, A4, A5, L1, A, L2 and R2 are as defined in the detailed description. The present invention also relates to a combination or a composition comprising the compound of Formula I.

  本发明涉及公式I的新化合物，其中，R1、A1、A2、A3、A4、A5、L1、A、L2和R2的定义如详细描述中所述。本发明还涉及包含公式I化合物的组合物或组成物。